Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020

BACKGROUND: Novel anticancer agents are initially evaluated in a palliative setting in phase I studies. The benefit–risk applying the selected dose from these phase I studies can be considered acceptable at time of registration, however, it is unknown if the optimal dose has been selected during dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Maliepaard, M., Carree, W., van Bussel, M.T.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586755/
https://www.ncbi.nlm.nih.gov/pubmed/34752995
http://dx.doi.org/10.1016/j.esmoop.2021.100301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586755/
https://www.ncbi.nlm.nih.gov/pubmed/34752995
http://dx.doi.org/10.1016/j.esmoop.2021.100301

Ejemplares similares